We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 2,911

Dietary supplement legal update
  • Porzio Bromberg & Newman PC
  • USA
  • April 15 2016

Since passage of the Dietary Supplement Health and Education Act of 1994 (DSHEA), the dietary supplement industry has grown to more than $35 billion


FTC Files No-AG Suit Against Pharmaceutical Companies
  • McGuireWoods LLP
  • USA
  • April 14 2016

On March 30, 2016, the Federal Trade Commission (FTC) filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against


There Was a Panel on What?? Notes on the ABA Antitrust Spring Meeting Panel on Marijuana Law
  • Baker & Hostetler LLP
  • USA
  • April 14 2016

Attendees at this year's Spring Meeting may have been surprised by an unexpected panel: an overview of the status of the law related to the


District Court Dismisses Tying and Bundling Claims, Holding that Medical-Surgical Distributor Failed to Show Market Power or Injury to Competition
  • Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • USA
  • April 12 2016

The federal district court for the District of Kansas recently dismissed claims by a medical products distributor that two of its competitors


LSU Hospital Operator May Proceed with Antitrust Suit Against Competing Health System
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • April 11 2016

The antitrust suit against Willis Knighton Medical Center will continue following the denial of its motion to dismiss. BRFHH Shreveport v. Willis


Drug pricing myths and realities
  • Hogan Lovells
  • USA
  • April 11 2016

Turing Pharmaceuticals CEO Martin Shkreli and his notorious $750 pill have brought new media attention and public outcry to the already contentious


FTC Challenges "No-AG" Agreement as Illegal Reverse Payment
  • Cooley LLP
  • USA
  • April 6 2016

On March 30 the US Federal Trade Commission filed suit in federal court alleging that settlements of patent litigation in the pharmaceutical industry


Royalty obligations when patents are revoked
  • Bristows LLP
  • European Union, USA
  • April 6 2016

Claire Smith says that although the Advocate General's opinion in Genentech may not come as much of a surprise, it highlights to lawyers the


United we fall? 6th Circuit holds that members of hospital network may not be a single entity under the antitrust laws
  • Porter Wright Morris & Arthur LLP
  • USA
  • April 6 2016

The U.S. Court of Appeals for the 6th Circuit recently issued an opinion with potential antitrust impact on joint venturesin the healthcare realm


FTC’s Latest “Pay for Delay” Action Focuses on Noncash “Payments” and New “Product Hopping” Theory of Harm
  • Baker & Hostetler LLP
  • USA
  • April 4 2016

The Federal Trade Commission (FTC) filed an antitrust complaint this week against Endo Pharmaceuticals and several generic companies, alleging that